FDA Approves First T-Cell Therapy for Tumors; Cell Therapy Innovations Surge with New Funding and Partnerships

February 22, 2024
FDA Approves First T-Cell Therapy for Tumors; Cell Therapy Innovations Surge with New Funding and Partnerships
Gene Therapy
Gene Therapy

  • The US FDA has approved AMTAGVI™ (lifileucel), a first-of-its-kind T-cell therapy for solid tumors, specifically for advanced melanoma.

  • MIP Discovery has raised £7 million in Series A financing to commercialize synthetic affinity reagents, which are integral to cell and gene therapy processes.

  • Charles River Laboratories International has partnered with Pluristyx to expand its portfolio of human pluripotent stem cells, including both embryonic and induced pluripotent stem cells (iPSCs).

  • These events collectively represent major progress in the cell and gene therapy sector, promising new avenues for treating a range of diseases.

Summary based on 1 source

Get a daily email with more Gene Therapy stories

Source

More Stories